<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04244656</url>
  </required_header>
  <id_info>
    <org_study_id>CRSP-ONC-002</org_study_id>
    <nct_id>NCT04244656</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma</brief_title>
  <official_title>A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-BCMA Allogeneic CRISPR-Cas9-Engineered T Cells (CTX120) in Subjects With Relapsed or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CRISPR Therapeutics AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CRISPR Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and&#xD;
      efficacy of CTX120 in subjects with relapsed or refractory multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study may enroll approximately 80 subjects in total.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 22, 2020</start_date>
  <completion_date type="Anticipated">January 2027</completion_date>
  <primary_completion_date type="Anticipated">November 2026</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A (dose escalation): Incidence of adverse events</measure>
    <time_frame>From CTX120 infusion up to 28 days post-infusion</time_frame>
    <description>Adverse events defined as dose-limiting toxicities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B (cohort expansion): Objective response rate</measure>
    <time_frame>From CTX120 infusion up to 60 months post-infusion</time_frame>
    <description>Objective response rate per International Myeloma Working Group (IMWG) response criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>From date of CTX120 infusion and date of disease progression or death due to any cause, assessed up to 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From date of CTX120 infusion until date of death due to any cause, assessed up to 60 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>CTX120</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered by IV infusion following lymphodepleting chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CTX120</intervention_name>
    <description>CTX120 B-cell maturation antigen (BCMA)-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components.</description>
    <arm_group_label>CTX120</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years.&#xD;
&#xD;
          2. Relapsed or refractory multiple myeloma, as defined by IMWG response criteria and&#xD;
             treatment with at least 2 prior lines of therapy.&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group performance status 0 or 1.&#xD;
&#xD;
          4. Adequate renal, liver, cardiac and pulmonary organ function&#xD;
&#xD;
          5. Female subjects of childbearing potential and male subjects must agree to use&#xD;
             acceptable method(s) of contraception from enrollment through at least 12 months after&#xD;
             CTX120 infusion.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Prior allogeneic stem cell transplant (SCT).&#xD;
&#xD;
          2. Less than 60 days from autologous SCT at time of screening and with unresolved serious&#xD;
             complications.&#xD;
&#xD;
          3. Prior treatment with any gene therapy or genetically modified cell therapy, including&#xD;
             CAR T cells or natural killer cells, or BCMA-directed therapy.&#xD;
&#xD;
          4. Evidence of direct central nervous system (CNS) involvement by multiple myeloma.&#xD;
&#xD;
          5. History or presence of clinically relevant CNS pathology such as a seizure disorder,&#xD;
             cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, any autoimmune&#xD;
             disease with CNS involvement.&#xD;
&#xD;
          6. Unstable angina, clinically significant arrhythmia, or myocardial infarction within 6&#xD;
             months of enrollment.&#xD;
&#xD;
          7. Active HIV, hepatitis B virus or hepatitis C virus infection.&#xD;
&#xD;
          8. Previous or concurrent malignancy, except basal cell or squamous cell skin carcinoma,&#xD;
             adequately resected and in situ carcinoma of cervix, or a previous malignancy that was&#xD;
             completely resected and has been in remission for ≥5 years.&#xD;
&#xD;
          9. Use of systemic anti-tumor therapy or investigational agent within 14 days prior to&#xD;
             enrollment.&#xD;
&#xD;
         10. Primary immunodeficiency disorder or active autoimmune disease requiring steroids&#xD;
             and/or other immunosuppressive therapy.&#xD;
&#xD;
         11. Women who are pregnant or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ewelina Morawa, MD</last_name>
    <role>Study Director</role>
    <affiliation>CRISPR Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials</last_name>
    <phone>+1 877-214-4634</phone>
    <email>MedicalAffairs@crisprtx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Knight Navigators</last_name>
      <email>navigators@ohsu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>AskSarah</last_name>
      <phone>615-329-7274</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Contacos</last_name>
      <email>Christine.Contacos@health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Health Network, Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Catala d'Oncologia Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maite San Miguel</last_name>
      <email>eecc@unav.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 24, 2020</study_first_submitted>
  <study_first_submitted_qc>January 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2020</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CAR T</keyword>
  <keyword>Allogeneic</keyword>
  <keyword>Multiple myeloma</keyword>
  <keyword>CRISPR-Cas9</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

